Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 20/20 | 0.75 |
| ▸ | CTSB | P07858 | 19/20 | 0.75 |
| ▸ | CTSS | P25774 | 15/20 | 0.75 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.58 |
| ▸ | CTSL | P07711 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8113806 | 0.86 | CTSK (1.00) | CTSKCTSBCTSSKCNH2CYP3A4 | |
| SCHEMBL4589750 | 0.85 | CTSK (0.94) | CTSKCTSBCTSSKCNH2CYP3A4 | |
| SCHEMBL8115758 | 0.83 | CTSK (1.00) | CTSKCTSBCTSSKCNH2 | |
| SCHEMBL8099124 | 0.83 | CTSK (0.75) | CTSKCTSBCTSSKCNH2CYP3A4 | |
| SCHEMBL8107396 | 0.81 | CTSK (1.00) | CTSKCTSBCTSSKCNH2CYP3A4 | |
| SCHEMBL8114182 | 0.81 | CTSB (0.77) | CTSKCTSBCTSSKCNH2CYP3A4 | |
| SCHEMBL8106040 | 0.79 | CTSB (0.74) | CTSKCTSBCTSSKCNH2CYP3A4 | |
| SCHEMBL4894615 | 0.79 | CTSK (0.87) | CTSKCTSBCTSSKCNH2CYP3A4 | |
| SCHEMBL8106264 | 0.79 | CTSB (0.75) | CTSKCTSBCTSSKCNH2CYP3A4 | |
| SCHEMBL4899778 | 0.78 | CTSK (0.89) | CTSKCTSBCTSSKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009001127-A1 | CYANOCYCLOPROPYLCARBOXAMIDES AS CATHEPSIN INHIBITORS | ASTRAZENECA AB (SE) | 2008-12-31 | — | — | WO | disclosed |